Enzo Biochem Appoints Four Executives At Enzo Life Sciences As Unit Adds Products And Platforms To More Aggressively Expand In Pharmaceutical And Clinical Markets
Enzo Biochem Inc. (NYSE:ENZ) announced today that it has added four
highly experienced executives at its Enzo Life Sciences subsidiary to
focus on rapidly evolving new pharmaceutical and clinical applications.
Enzo Biochem Inc. (NYSE:ENZ) announced today that it has added four highly experienced executives at its Enzo Life Sciences subsidiary to focus on rapidly evolving new pharmaceutical and clinical applications. The officers, all filling newly created positions, are Bruce Taillon, PhD, as head of global technology business development, John D’Errico, PhD, to lead the commercial merchandising operations , Kara Cannon, as head of global marketing and Paul Munger, PhD, to lead Global Manufacturing. Over the past two years, Enzo has been engaged in enhancing the Life Sciences subsidiary’s operating performance through added capabilities, greater integration and a more focused product mix. These efforts are all aimed at significantly expanding Enzo’s presence and marketing beyond the traditional academic and research laboratory core to greater penetrate the pharmaceutical and clinical customer base with new and cutting edge platform technologies. “Enzo Life Sciences has developed numerous new products to meet the demands of these exciting growth markets and our investment in people—which we are announcing today—is a manifestation of our commitment to this exciting strategy. All four individuals are highly experienced, with technical expertise and impressive professional and commercial accomplishments; we are confident they will all make notable contributions to our Company’s growth,” says Barry Weiner, Enzo Biochem President. Among the additions to Enzo Life Sciences’ offerings is a line of specific products and assays aimed at, among other areas, epigenetics, a burgeoning new approach to studying genetic variations in treatments and drug discoveries among large and small pharma. Enzo Life Sciences’ emphasis is increasingly on developing platforms and products to meet the expanding needs of new and revolutionary pharmacological and genetic treatments, which often require extensive pre-clinical testing. In addition, these added capabilities will materially enhance the broader esoteric diagnostic direction at Enzo Clinical Labs, another subsidiary of Enzo Biochem, which is itself focused on greater national recognition and expanding the use of its higher value molecular testing capabilities.